000300621 001__ 300621
000300621 005__ 20250423112817.0
000300621 0247_ $$2doi$$a10.21037/tlcr-2025-204
000300621 0247_ $$2pmid$$apmid:40248736
000300621 0247_ $$2pmc$$apmc:PMC12000956
000300621 0247_ $$2ISSN$$a2218-6751
000300621 0247_ $$2ISSN$$a2226-4477
000300621 037__ $$aDKFZ-2025-00835
000300621 041__ $$aEnglish
000300621 082__ $$a610
000300621 1001_ $$aHu, Bowen$$b0
000300621 245__ $$aIdentification and validation of crotonylation-related diagnostic markers for lung adenocarcinoma via weighted correlation network analysis and machine learning.
000300621 260__ $$a[Erscheinungsort nicht ermittelbar]$$b[Verlag nicht ermittelbar]$$c2025
000300621 3367_ $$2DRIVER$$aarticle
000300621 3367_ $$2DataCite$$aOutput Types/Journal article
000300621 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1745328706_26882
000300621 3367_ $$2BibTeX$$aARTICLE
000300621 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300621 3367_ $$00$$2EndNote$$aJournal Article
000300621 520__ $$aLung adenocarcinoma (LUAD) is one of the most common tumors in terms of incidence and mortality worldwide. Posttranslational modifications, including crotonylation, play a crucial role in various biological processes and diseases. However, the role of crotonylation in LUAD remains unclear. Our research focuses on identifying key genes in LUAD that are linked to crotonylation and prognosis. We also aim to clarify their role in the LUAD microenvironment to advance clinical translation of related targets.We used RNA-sequencing data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) database to identify differentially expressed genes (DEGs) related to crotonylation in LUAD. Weighted correlation network analysis (WGCNA) was applied to construct gene networks, and hub genes were identified using protein-protein interaction (PPI) analysis. The prognostic value of hub genes was assessed using Kaplan-Meier plots, and the correlation with immune infiltration was analyzed via Tumor Immune Estimation Resource (TIMER) and other algorithms. We then verified these genes through clinical samples and confirmed the role of MMACHC in LUAD.We identified GAPDH, SLC25A13, MMACHC, and HDAC1 as potential crotonylation-related biomarkers for LUAD. These genes were found to be overexpressed in LUAD and were associated with poor prognosis. They also showed significant correlations with immune cell infiltration and immune-inflammatory pathways. Functional experiments confirmed that MMACHC knockdown inhibited cell proliferation and migration, induced apoptosis, and enhanced the efficacy of immunotherapy in LUAD.Our study suggests that crotonylation-related genes, particularly MMACHC, may serve as novel therapeutic targets and diagnostic markers for LUAD.
000300621 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000300621 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300621 650_7 $$2Other$$aCrotonylation
000300621 650_7 $$2Other$$abiomarkers
000300621 650_7 $$2Other$$aimmunotherapy
000300621 650_7 $$2Other$$alung adenocarcinoma (LUAD)
000300621 650_7 $$2Other$$aweighted correlation network analysis (WGCNA)
000300621 7001_ $$aChen, Xin$$b1
000300621 7001_ $$aZou, Dan$$b2
000300621 7001_ $$aDu, Xiaoyue$$b3
000300621 7001_ $$aFeng, Sitong$$b4
000300621 7001_ $$aShen, Yiwen$$b5
000300621 7001_ $$aSha, Xiaofeng$$b6
000300621 7001_ $$aJiang, Feng$$b7
000300621 7001_ $$aZhou, Guoren$$b8
000300621 7001_ $$aLin, Fan$$b9
000300621 7001_ $$0P:(DE-HGF)0$$aKäsmann, Lukas$$b10
000300621 7001_ $$aShen, Bo$$b11
000300621 773__ $$0PERI:(DE-600)2754335-3$$a10.21037/tlcr-2025-204$$gVol. 14, no. 3, p. 940 - 962$$n3$$p940 - 962$$tTranslational Lung Cancer Research$$v14$$x2218-6751$$y2025
000300621 909CO $$ooai:inrepo02.dkfz.de:300621$$pVDB
000300621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000300621 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000300621 9141_ $$y2025
000300621 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000300621 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000300621 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000300621 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-20
000300621 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-20
000300621 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-20
000300621 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000300621 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bTRANSL LUNG CANCER R : 2022$$d2024-12-20
000300621 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-20
000300621 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000300621 980__ $$ajournal
000300621 980__ $$aVDB
000300621 980__ $$aI:(DE-He78)MU01-20160331
000300621 980__ $$aUNRESTRICTED